**AMENDMENTS TO THE CLAIMS**:

This listing of claims will replace all prior versions, and listings, of claims in the application:

LISTING OF CLAIMS

1-6. (canceled)

7. (previously presented) A peptide compound comprising a sequence of at least 8 consecutive amino acids, said peptide being able to induce a specific T-cell immune response, the amino acid sequence being selected from the group consisting of SLFEGIDIY (SEQ ID No 1) and SLFEGIDIYT (SEQ ID No 2).

8-9. (canceled)

10. (previously presented) The peptide compound as claimed in claim 7, wherein the amino acid sequence is SEQ ID No. 1.

11. (previously presented) The peptide compound as claimed in claim 7, further comprising at least one element selected from the group consisting of:

- a protective chemical group able to protect peptides against proteases and reacting with NH2 or COOH, or with both NH2 and COOH, provided that this modification does not significantly lower the immunogenicity of the peptide,

- chemical groups improving the effectiveness of a vaccine in vivo,

- lipids or fatty acids, covalently linked to the peptide fragments so as to form lipopeptides,

- a carrier protein possessing restriction sites and enabling intact peptide fragments to be conveyed to their sites of action in the body.

12. (canceled)

13. (previously presented) A vector for expressing the peptide compound as claimed in claim 7, comprising a DNA fragment encoding for said peptide compound, wherein the DNA fragment is fused to a promoter that is strong and effective in eukaryotic or in prokaryotic cells or in both eukaryotic and prokaryotic cells.

14. (previously presented) The vector as claimed in claim 13, further comprising at least one selection

marker and, optionally, at least one coding sequence for cytokines or lymphokines or for both cytokines and lymphokines.

15. (previously presented) The vector as claimed in claim 13, wherein the vector is chosen form a viral vector, a plasmid, and a pseudovector.

16-18. (canceled)

19. (currently amended) A ~~pharmaceutical~~ composition comprising a peptide compound according to claim 7 and a pharmaceutically acceptable vehicle.

20. (currently amended) The ~~pharmaceutical~~ composition as claimed in claim 19, further comprising at least one immunological adjuvant.

21. (currently amended) A ~~pharmaceutical~~ composition comprising a vector as claimed in claim 13 and a pharmaceutically acceptable vehicle.

22-29. (canceled)

30. (currently amended) The ~~pharmaceutical~~ composition as claimed in claim 19, comprising a pharmaceutical vehicle which is compatible with IV, subcutaneous, oral or nasal administration.

31. (currently amended) The ~~pharmaceutical~~ composition as claimed in claim 19 further comprising a pharmaceutical vehicle chosen from positively charged liposomes, negatively charged liposomes, nanoparticles, and lipid emulsions.

32-33. (canceled)

34. (currently amended) A method for ~~systemic immunization of~~ treating a tumor(s), comprising administering to a patient ~~a medicinal~~ an effective amount of a product comprising a peptide compound comprising a sequence of at least 8 consecutive amino acids, the amino acid sequence being selected from the group consisting of SLFEGIDIY (SEQ ID No 1) and SLFEGIDIYT (SEQ ID No 2)~~, and wherein the peptide compound brings about a specific T-cell immune response~~.

35. (currently amended) A method for ~~immunizing by direct injection in a tumor(s)~~ treating a patient having

renal carcinoma, comprising administering to [[a]] said patient ~~a medicinal~~ an effective amount of a product comprising a sequence of at least 8 consecutive amino acids, the amino acid sequence being selected from the group consisting of SLFEGIDIY (SEQ ID No 1) and SLFEGIDIYT (SEQ ID No 2)~~, and wherein the peptide compound brings about a specific T cell immune response~~.

36-63. (canceled)

64. (currently amended) A ~~pharmaceutical~~ composition comprising a peptide compound according to claim 10 and a pharmaceutically acceptable vehicle.

65. (canceled)